Related Experiment Videos

We've made progress, but there's a long way to go

Patricia Schroeder

Journal of Nursing Care Quality

|April 12, 2003

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.

Blood advances·2024

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.

The Journal of pharmacology and experimental therapeutics·2022

Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.

Clinical pharmacology in drug development·2022

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

Journal of medicinal chemistry·2021

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.

Diabetes, obesity & metabolism·2020

Abnormal brain structure and behavior in MyD88-deficient mice.

Brain, behavior, and immunity·2020

See all related articles